Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

Item

http://www.wikidata.org/entity/Q27332192

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

@nl

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

@ast

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

@en

type

Item

label

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

@nl

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

@ast

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

@en

prefLabel

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

@nl

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

@ast

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

@en

P1476

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

@en

P2093

A Perera

http://www.w3.org/2001/XMLSchema#string

A Prats

http://www.w3.org/2001/XMLSchema#string

B E Acevedo

http://www.w3.org/2001/XMLSchema#string

C A Casacó

http://www.w3.org/2001/XMLSchema#string

C M Valenzuela

http://www.w3.org/2001/XMLSchema#string

CERVIFARM-300-II Study Group

http://www.w3.org/2001/XMLSchema#string

D F Alonso

http://www.w3.org/2001/XMLSchema#string

I Baladrón

http://www.w3.org/2001/XMLSchema#string

I García

http://www.w3.org/2001/XMLSchema#string

I Hernández

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside

Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.

Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.

Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.

Targeting CK2 for cancer therapy.

P2888

bjc.2015.137

P304

1636-1643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4912790

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/BJC.2015.137

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1006458970

http://www.w3.org/2001/XMLSchema#string

P698

25880012

http://www.w3.org/2001/XMLSchema#string

P932

4430720

http://www.w3.org/2001/XMLSchema#string